Ten-year experience with transcatheter and surgical aortic valve replacement in Finland

Aim: We investigated the outcomes of transcatheter (TAVR) and surgical aortic valve replacement (SAVR) in Finland during the last decade. Methods: The nationwide FinnValve registry included data from 6463 patients who underwent TAVR or SAVR with a bioprosthesis for aortic stenosis from 2008 to 2017....

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of medicine (Helsinki) 2019-05, Vol.51 (3-4), p.270-279
Hauptverfasser:	Mäkikallio, Timo, Jalava, Maina P., Husso, Annastiina, Virtanen, Marko, Laakso, Teemu, Ahvenvaara, Tuomas, Tauriainen, Tuomas, Maaranen, Pasi, Kinnunen, Eeva-Maija, Dahlbacka, Sebastian, Jaakkola, Jussi, Airaksinen, Juhani, Anttila, Vesa, Savontaus, Mikko, Laine, Mika, Juvonen, Tatu, Valtola, Antti, Raivio, Peter, Eskola, Markku, Niemelä, Matti, Biancari, Fausto
Format:	Artikel
Sprache:	eng
Schlagworte:	Acute Kidney Injury - epidemiology Aged Aged, 80 and over Aortic Valve - pathology aortic valve stenosis (AS) Aortic Valve Stenosis - mortality Aortic Valve Stenosis - surgery Erythrocyte Transfusion - statistics & numerical data Female Finland - epidemiology Heart Valve Prosthesis - adverse effects Hemorrhage - epidemiology Humans Length of Stay - statistics & numerical data Male Mortality Outcome Assessment, Health Care Registries Retrospective Studies Severity of Illness Index surgical aortic valve replacement (SAVR) Survival Analysis Time Factors Transcatheter aortic valve implantation (TAVI) Transcatheter Aortic Valve Replacement - adverse effects Transcatheter Aortic Valve Replacement - methods Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Aim: We investigated the outcomes of transcatheter (TAVR) and surgical aortic valve replacement (SAVR) in Finland during the last decade. Methods: The nationwide FinnValve registry included data from 6463 patients who underwent TAVR or SAVR with a bioprosthesis for aortic stenosis from 2008 to 2017. Results: The annual number of treated patients increased three-fold during the study period. Thirty-day mortality declined from 4.8% to 1.2% for TAVR (p = .011) and from 4.1% to 1.8% for SAVR (p = .048). Two-year survival improved from 71.4% to 83.9% for TAVR (p
ISSN:	0785-3890 1365-2060
DOI:	10.1080/07853890.2019.1614657